




**FDC Limited**

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS



## FDC Limited reports Q1FY23 results

Mumbai, 4<sup>th</sup> Aug 2022 (Date): FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the first quarter ended 30<sup>th</sup> June 2022.



### Consolidated Q1FY23 FDC reported

Rs. in crores	Q1' 22-23	Q1' 21-22	YOY Growth
Operating Revenues	494.66	447.47	10.5%
EBITDA	97.13	138.67	-30.0%
EBITDA %	19.6%	31.0%	
PBT	87.05	128.30	-32.2%
PAT	70.66	97.84	-27.8%
EPS (Rs.)	4.23	5.80	-27.1%

### Commenting on the results;

We have registered good growth for the quarter across all our business segments and will strive to do the same for the year. The domestic business has registered a single-digit growth on the huge base of last year. This was driven by robust demand across our established therapies and brands. We have registered good QoQ and YoY growth in the Export Formulation and API business. However, there are impacts on the margin and profits because of the continuous increase in RM and PM prices across products, and this rise is on the higher side compared to the FG price increase that we have taken.

### India Market:

The sale of branded formulations in India for Q1FY23 was Rs. 421.03 crores, with a growth of 8% on YoY and 52% on QoQ. Overall sales in the Indian market accounted for 85% of total consolidated sales for the quarter.

Registered Office: Waluj, Aurangabad, Maharashtra - 431 136, India

CORPORATE OFFICE : MZ-18, G.W. Road, Jogeshwar (W), Mumbai - 400 102, INDIA  
Tel.: +91-22-3071 9100 - 399 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2678 6393 / 8123 / 1912  
E-mail : fdc@fdcindia.com • Website : www.fdcindia.com

REGISTERED OFFICE : B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA  
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299  
E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176

As per secondary sales data by IQVIA for the quarter ended June 30, 2022, the Company delivered strong YoY growth of 21.6% compared to the Indian Pharmaceutical Market (IPM) growth of 17.2% YoY. This growth was mainly driven by Big brands like Zifi, Electral and Enerzal which witnessed a good volume growth. Electral has moved up to 34<sup>th</sup> in IPM in MAT Jun'22 as compared to 37<sup>th</sup> in the same period last year.

Further, the company was the 2<sup>nd</sup> fastest growing company in Jun'22 month among the Top 25 corporates.

### **Export Formulations Market:**

Formulation Sales in the Export market were Rs. 54.56 crores in Q1FY23, up by 26.5% over YoY and up by 15% over QoQ and accounted for 11% of total consolidated sales. The main contributor is the USA market, accounting for 52% of total Export Formulations Sales.

ANDA is filed for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%.

### **Export API Market:**

API Sales in the Export market were Rs. 17.37 crores in Q1FY23, up by 25% over YoY and up by 21% over QoQ and accounted for 4% of total consolidated sales.

### **ABOUT FDC LTD**

FDC was established in the year 1936 as a partnership firm. This firm was incorporated as a Company in 1940, with the vision of building a world-class company while contributing to making the nation self-reliant in healthcare. To cite a few, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE. FDC is a forerunner in the manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmics. FDC has also set up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life for millions globally.

### **Disclaimer**

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve several risks and uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.



Registered Office: Waluj, Aurangabad, Maharashtra – 431 136. India